SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 28, 2005
Seattle Genetics, Inc.
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of
incorporation or organization)
|(Commission File Number)
21823 30th Drive SE
Bothell, Washington 98021
(Address of principal executive offices, including zip code)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry Into a Material Definitive Agreement.
On April 28, 2005, Seattle Genetics, Inc. (Seattle Genetics) entered into an agreement with MedImmune, Inc. (MedImmune) granting MedImmune rights to Seattle Genetics antibody-drug conjugate (ADC) technology (the MedImmune Agreement). Pursuant to the MedImmune Agreement, MedImmune will pay an upfront fee of $2.0 million for rights to utilize Seattle Genetics ADC technology with antibodies against a single tumor target that MedImmune has selected. MedImmune also has an option to pay an additional fee to access Seattle Genetics ADC technology for a second proprietary antibody program. Under the terms of the MedImmune Agreement, MedImmune has agreed to make progress-dependent milestone payments and pay royalties on net sales of any resulting ADC products. MedImmune is responsible for research, product development, manufacturing and commercialization of all products under the MedImmune Agreement. Seattle Genetics will receive material supply and annual maintenance fees as well as research support payments for any assistance provided to MedImmune in developing ADC products. The MedImmune Agreement will be filed as an exhibit to the Companys quarterly report on Form 10-Q for the quarter ending June 30, 2005, with portions omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.
Seattle Genetics does not have any material relationship with MedImmune or its affiliates.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this report regarding the Companys business that are not historical facts are forward-looking statements that involve risks and uncertainties. For a discussion of these risks and uncertainties, any of which could cause the Companys actual results to differ from those contained in the forward-looking statement, see the section entitled Important Factors That May Affect Our Business, Results of Operations and Stock Price in the Companys Annual Report on Form 10-K for the year ended December 31, 2004 and discussions of potential risks and uncertainties in the Companys subsequent filings with the SEC.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|SEATTLE GENETICS, INC.
|Date: May 3, 2005
/s/ Clay B. Siegall
Clay B. Siegall
President and Chief Executive Officer